KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Invested Capital (2021 - 2023)

AbCellera Biologics (ABCL) has disclosed Return on Invested Capital for 3 consecutive years, with 0.16% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Return on Invested Capital fell 28.0% year-over-year to 0.16%, compared with a TTM value of 0.16% through Dec 2023, down 28.0%, and an annual FY2024 reading of 0.23%, down 6.0% over the prior year.
  • Return on Invested Capital was 0.16% for Q4 2023 at AbCellera Biologics, down from 0.14% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.19% in Q3 2022 and bottomed at 0.16% in Q4 2023.
  • Average Return on Invested Capital over 3 years is 0.03%, with a median of 0.11% recorded in 2022.
  • The sharpest move saw Return on Invested Capital dropped -3bps in 2022, then crashed -32bps in 2023.
  • Year by year, Return on Invested Capital stood at 0.14% in 2021, then dropped by -21bps to 0.11% in 2022, then tumbled by -246bps to 0.16% in 2023.
  • Business Quant data shows Return on Invested Capital for ABCL at 0.16% in Q4 2023, 0.14% in Q3 2023, and 0.1% in Q2 2023.